Pfizer CEO Albert Bourla is reportedly reconsidering parts of the company’s planned German investments after Germany’s proposed healthcare reforms raised concerns about predictability for drug spending and market access. Reuters reported that Bourla wrote to Chancellor Friedrich Merz describing the uncertainty around long-term investment planning. The reform framework aims to save 16.3 billion euros in 2027 and includes drug spending measures intended to generate 1.9 billion euros next year. The package includes changes such as increased markdown requirements on product list prices for insurers. Reuters noted that other global drugmakers had already cut planned investment levels in Germany, including Eli Lilly and Boehringer Ingelheim, following similar concerns. Novartis CEO Vas Narasimhan previously criticized the signals sent to an innovation-heavy industry. The practical implication is capital timing and location: when reimbursement policies appear less stable, multinational pharma may slow or re-scope investments that rely on predictable uptake and launch economics.